Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate Glucuronosyltransferase

The default assumption during in vitro in vivo extrapolation (IVIVE) to predict metabolic clearance in physiologically based pharmacokinetics (PBPK) is that protein expression and activity have the same relationship in various tissues. This assumption is examined for uridine 5′-diphosphate glucuronosyltransferases (UGTs), a case example where expression and hence metabolic activity are distributed across various tissues. Our literature analysis presents overwhelming evidence of a greater UGT activity per unit of enzyme (higher kcat) in kidney and intestinal tissues relative to liver (greater than 200-fold for UGT2B7). This analysis is based on application of abundance values reported using similar proteomic techniques and within the same laboratory. Our findings call into question the practice of assuming similar kcat during IVIVE estimations as part of PBPK and call for a systematic assessment of the kcat of various enzymes across different organs. The analysis focused on compiling data for probe substrates that were common for two or more of the studied tissues to allow for reliable comparison of cross-tissue enzyme kinetics; this meant that UGT enzymes included in the study were limited to UGT1A1, 1A3, 1A6, 1A9, and 2B7. Significantly, UGT1A9 (n = 24) and the liver (n = 27) were each found to account for around half of the total dataset; these were found to correlate with hepatic UGT1A9 data found in 15 of the studies, highlighting the need for more research into extrahepatic tissues and other UGT isoforms. SIGNIFICANCE STATEMENT During physiologically based pharmacokinetic modeling (in vitro in vivo extrapolation) of drug clearance, the default assumption is that the activity per unit of enzyme is the same in all tissues. The analysis provides preliminary evidence that this may not be the case and that renal and intestinal tissues may have almost 250-fold greater uridine 5′-diphosphate glucuronosyltransferase activity per unit of enzyme than liver tissues.

[1]  A. Galetin,et al.  Quantitative Proteomic Map of Enzymes and Transporters in the Human Kidney: Stepping Closer to Mechanistic Kidney Models to Define Local Kinetics , 2021, Clinical pharmacology and therapeutics.

[2]  Amin Rostami-Hodjegan,et al.  Physiological‐based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platforms , 2020, Biopharmaceutics & drug disposition.

[3]  A. Rowland,et al.  Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. , 2020, Pharmacology & therapeutics.

[4]  Pamela J Davies,et al.  Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine , 2020, Drug Metabolism and Disposition.

[5]  M. Rowland,et al.  Commentary: Hepatic Clearance Concepts and Misconceptions: Why the Well-Stirred Model Is Still Used Even Though It Is Not Physiologic Reality? , 2019, Biochemical pharmacology.

[6]  N. Qiu,et al.  Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry , 2018, Drug Metabolism and Disposition.

[7]  A. Rostami-Hodjegan,et al.  Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics , 2018, Expert opinion on drug metabolism & toxicology.

[8]  Mingyao Liu,et al.  Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes. , 2018, Toxicology letters.

[9]  U. Broeckel,et al.  Age‐ and Genotype‐Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate‐Glucuronosyltransferases in Human Liver , 2018, Clinical pharmacology and therapeutics.

[10]  T. Goosen,et al.  Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5′-Diphosphate–Glucuronosyltransferase Enzymes with Reference to Catalytic Activity , 2018, Drug Metabolism and Disposition.

[11]  T. Goosen,et al.  Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity , 2017, Drug Metabolism and Disposition.

[12]  A. Galetin,et al.  Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance , 2017, Drug Metabolism and Disposition.

[13]  A. Galetin,et al.  Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation , 2016, The AAPS Journal.

[14]  P. Potter,et al.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance , 2016, The AAPS Journal.

[15]  K. Knights,et al.  Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. , 2016, British journal of clinical pharmacology.

[16]  P. Robinson,et al.  Enzymes: principles and biotechnological applications , 2015, Essays in biochemistry.

[17]  Dong-Hyun Kim,et al.  In Vitro Assay of Six UDP-Glucuronosyltransferase Isoforms in Human Liver Microsomes, Using Cocktails of Probe Substrates and Liquid Chromatography–Tandem Mass Spectrometry , 2014, Drug Metabolism and Disposition.

[18]  A. Rostami-Hodjegan,et al.  Protein expression of various hepatic uridine 5′‐diphosphate glucuronosyltransferase (UGT) enzymes and their inter‐correlations: a meta‐analysis , 2014, Biopharmaceutics & drug disposition.

[19]  Shuxing Zhang,et al.  Quantitative prediction of glucuronidation in humans using the in vitro- in vivo extrapolation approach. , 2013, Current topics in medicinal chemistry.

[20]  A. Galetin,et al.  Application of a Physiologically Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation: Utility of In Vitro and In Vivo Data , 2013, Drug Metabolism and Disposition.

[21]  J. Bauman,et al.  Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors , 2012, Drug Metabolism and Disposition.

[22]  A. Galetin,et al.  Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin , 2012, Drug Metabolism and Disposition.

[23]  Masahiro Iwaki,et al.  In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences , 2011, Drug metabolism reviews.

[24]  A. Rostami-Hodjegan,et al.  Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors , 2011, Biopharmaceutics & drug disposition.

[25]  Guangbo Ge,et al.  Determination of propofol UDP-glucuronosyltransferase (UGT) activities in hepatic microsomes from different species by UFLC-ESI-MS. , 2011, Journal of pharmaceutical and biomedical analysis.

[26]  C. Guillemette,et al.  Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants , 2009, Drug Metabolism and Disposition.

[27]  A. Galetin,et al.  Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance , 2009, Pharmaceutical Research.

[28]  Ying Zhang,et al.  In Silico Modeling of Nonspecific Binding to Human Liver Microsomes , 2008, Drug Metabolism and Disposition.

[29]  Andrew Rowland,et al.  The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities , 2008, Drug Metabolism and Disposition.

[30]  Y. Kato,et al.  Asymmetric Intestinal First-Pass Metabolism Causes Minimal Oral Bioavailability of Midazolam in Cynomolgus Monkey , 2007, Drug Metabolism and Disposition.

[31]  A. Galetin,et al.  Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.

[32]  Koujirou Yamamoto,et al.  Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver , 2006, European Journal of Clinical Pharmacology.

[33]  J Brian Houston,et al.  BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT , 2006, Drug Metabolism and Disposition.

[34]  J. Ritter,et al.  AN INVESTIGATION OF HUMAN AND RAT LIVER MICROSOMAL MYCOPHENOLIC ACID GLUCURONIDATION: EVIDENCE FOR A PRINCIPAL ROLE OF UGT1A ENZYMES AND SPECIES DIFFERENCES IN UGT1A SPECIFICITY , 2005, Drug Metabolism and Disposition.

[35]  A. Prémaud,et al.  IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM , 2005, Drug Metabolism and Disposition.

[36]  Amin Rostami-Hodjegan,et al.  Cytochrome P450 3A expression and activity in the human small intestine , 2004, Clinical pharmacology and therapeutics.

[37]  Oliver Burk,et al.  Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.

[38]  B. Ring,et al.  The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[39]  B. Burchell,et al.  Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[40]  J. Brockmöller,et al.  Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. , 2014, Pharmacology & therapeutics.

[41]  M. Shimizu,et al.  Effects of propofol analogs on glucuronidation of propofol, an anesthetic drug, by human liver microsomes. , 2007, Drug metabolism letters.